Search for content, post, videos

Zerion Pharma elects new board members

Goesch and Lykke Thomsen

Zerion Pharma has elected two new members, Dr. Torsten Goesch and Dr. Lars Lykke Thomsen, to join its board of directors.

“We are thrilled to welcome Dr Torsten Goesch and Dr Lars Lykke Thomsen to our board. They are both outstanding pharma industry leaders and will be able to support Zerion with invaluable insights from their vast professional experience. We are looking into two important events within the next 12 months: A listing on NASDAQ First North and preparing for our first clinical trial in humans of a Dispersome drug formulation. Together, Torsten and Lars have an excellent background to secure that we can accomplish these goals,” says Ole Wiborg, CEO of Zerion.

“We are looking into two important events within the next 12 months: A listing on NASDAQ First North and preparing for our first clinical trial in humans of a Dispersome drug formulation.”

Dr. Torsten Goesch is an experienced life science venture capital investor and has been a partner and director at Rosetta Capital since 2002, states the company in a press release. Goesch is also the founder and former managing director of TRG invest, a Munich-based consultancy serving companies in the life science sector. Prior to his role at Rosetta capital he was the general manager of Biogen in Europe from 1997 to 1999 and before this he was the commercial head of Merck KGaA’s generic drug business, Merck Generics.

Dr. Lars Lykke Thomsen is an experienced life sciences and pharmaceutical executive with a strong clinical and scientific background, states the company in a press release. He has 20 years of R&D experience from the pharmaceutical industry including CROs providing strategic and operational leadership in drug development programs and 20 years of management experience in pharmaceutical companies. He is currently the Chief Medical Officer in Pharmacosmos A/S, a Danish pharmaceutical company specialized in manufacturing and development of compounds for treating iron deficiency with or without anaemia.

Photo of Torsten Goesch (Photo: ProMore Pharma) and Lars Lykke Thomsen (Photo: Pharmacosmos)